Ausgabe 1/2016
Inhalt (14 Artikel)
Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles
Francesca Pistollato, Susanne Bremer-Hoffmann, Giuseppe Basso, Sandra Sumalla Cano, Iñaki Elio, Manuel Masias Vergara, Francesca Giampieri, Maurizio Battino
Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review
Norbertus A. Ipenburg, Koos Koole, K. Seng Liem, Pauline M. W. van Kempen, Ron Koole, Paul J. van Diest, Robert J. J. van Es, Stefan M. Willems
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Katrin Liffers, Katarina Kolbe, Manfred Westphal, Katrin Lamszus, Alexander Schulte
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis
Gaetan Des Guetz, Thierry Landre, Bernard Uzzan, Kader Chouahnia, Patrick Nicolas, Jean-François Morere
RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Jin Liu, Zhixin Sheng, Yanxia Zhang, Guixin Li
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
N. Kramkimel, A. Thomas-Schoemann, L. Sakji, JL. Golmard, G. Noe, E. Regnier-Rosencher, N. Chapuis, E. Maubec, M. Vidal, MF. Avril, F. Goldwasser, L. Mortier, N. Dupin, B. Blanchet
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
Christelle de la Fouchardiere, Nadia Oussaid, Olfa Derbel, Myriam Decaussin-Petrucci, Marie-Eve Fondrevelle, Qing Wang, Pierre-Paul Bringuier, Claire Bournaud-Salinas, Jean-Louis Peix, Jean-Christophe Lifante, Anne-Laure Giraudet, Jonathan Lopez, Françoise Borson-Chazot
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort
Magali Rouyer, Denis Smith, Christophe Laurent, Yves Becouarn, Rosine Guimbaud, Pierre Michel, Nicole Tubiana-Mathieu, Aurélie Balestra, Jérémy Jové, Philip Robinson, Pernelle Noize, Nicholas Moore, Alain Ravaud, Annie Fourrier-Réglat
Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients
Kazuhiro Yamamoto, Kazuaki Shinomiya, Takeshi Ioroi, Sachi Hirata, Kenichi Harada, Manabu Suno, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Tsutomu Nakagawa, Takeshi Hirano, Toshinori Bito, Chikako Nishigori, Hideaki Miyake, Masato Fujisawa, Midori Hirai
HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases
Haruhiko Dozono, Shintaro Yanazume, Hideaki Nakamura, Tomáš Etrych, Petr Chytil, Karel Ulbrich, Jun Fang, Takeshi Arimura, Tsutomu Douchi, Hiroaki Kobayashi, Michiaki Ikoma, Hiroshi Maeda
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
Sarah L. Greig
Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow”
Samer Tabchi, Marwan Ghosn